Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Medical Therapy for ANOCA (MVP-ANOCA)
NCT06424834Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amlodipine, nebivolol in Angina with non-obstructive coronary arteries (ANOCA), microvascular angina (MVA), vasospastic angina (VSA), myocardial bridge (MB), sponsored by Stanford University. Started Oct 2024; status: recruiting.
02
Drugs
amlodipinenebivolol
03
Conditions
Angina with non-obstructive coronary arteries (ANOCA)microvascular angina (MVA)vasospastic angina (VSA)myocardial bridge (MB)
Beyond the preview
Go deeper on NCT06424834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424834.